
HPLC purity describes the proportion of an integrated chromatographic signal assigned to the target peptide under a stated method. Peptide content describes how much peptide is present in a quantity of supplied material. A buyer needs both the measurement definition and its reporting basis before comparing certificates of analysis.
What does an HPLC purity result measure?
On a reversed-phase HPLC report, a purity figure commonly comes from the target peak area divided by the sum of the integrated peak areas. The result depends on the separation, detector response and integration rules. Ask the laboratory to identify what it included in that calculation. A percentage without a method reference leaves those choices unclear.
Identity, purity and assay answer different analytical questions. The EMA’s current ICH Q2(R2) page lists these as distinct purposes of analytical procedures and identifies accuracy, precision and specificity among the relevant validation concepts. Its stated scope concerns pharmaceutical analytical procedures. A cosmetic raw-material buyer can use these distinctions to ask better questions without treating pharmaceutical guidance as an automatic cosmetic specification.
A chromatogram needs context
- The method identifier and revision should match the result on the COA.
- The report should state whether purity is an area percentage, a corrected result or another defined quantity.
- Related peaks, reporting thresholds and integration rules should be available for technical review when they affect acceptance.
- The identity evidence should relate to the same batch and agreed peptide identity.
A matching mass signal from LC-MS can support an identity assessment. It does not, by itself, establish the amount of peptide in the container. The agreement should say which evidence establishes identity and which result establishes content.
Why supplied powder mass and peptide content can differ
A weighed portion can contain the peptide together with counterions, water and other constituents. The analytical basis determines how the laboratory handles those contributions. Terms such as “as received,” “anhydrous” and “free peptide” therefore need definitions in the specification.
A 2023 USP-authored paper on synthetic peptide reference standards describes a mass-balance approach that accounts for peptide-related impurities, counterions, water, residual solvents and inorganic residues. Its theoretical example gives 0.93 mg of free-base peptide per mg of material on an anhydrous basis. That example illustrates a measurement basis; it is not a specification for PeptideVaultPro products.
Put the basis beside the number
| Reported item | Clarification to request | Purchasing consequence |
|---|---|---|
| HPLC purity, % area | Detector, integration rules and method reference | Compare like analytical results |
| Peptide content, mg/mg or % | Assay approach, reference standard and correction basis | Understand the quantity of peptide represented by the powder |
| Water content | Method, sampling date and reporting basis | Assess whether the content calculation applies to the supplied material |
| Counterion result | Identity and quantity, where relevant to the agreed material | Keep the quoted chemical form consistent |
| Vial quantity | Total fill mass, peptide mass or another declared quantity | Avoid interpreting two different quantities as the same offer |
Compare offers on a common declared basis
Consider an illustrative commercial comparison: two suppliers each offer a 100 mg pack. One describes the pack as 100 mg of supplied powder; the other describes a peptide-equivalent quantity. Even if both COAs show a similar chromatographic purity, the offers cannot be compared until the quantity definitions agree. The example describes a document problem, not a recommended formulation amount.
Ask both suppliers to complete the same specification fields. If a figure is unavailable, record that gap in the quotation review. Converting an unknown result into a favourable assumption can hide a real difference in the offers.
- Confirm the peptide identity, chemical form and supplier product code.
- Record the required quantity and the basis on which it is sold.
- Request the offered batch COA and the definitions of its purity and content results.
- Ask who assigns the reference standard value and which report supports it.
- Resolve differences with the laboratory before setting the purchase acceptance criterion.
What to do when two laboratories disagree
Start with sample identity, storage history, method revision and reporting basis. Then compare reference-standard assignments and the treatment of related peaks. A difference between two reports needs a documented investigation; repeating analyses until a preferred number appears leaves the original discrepancy unresolved.
The receiving laboratory should state whether it can use the supplier’s method, needs a method transfer or proposes an independently justified procedure. Include that work in the quality agreement when testing is outsourced.
Frequently asked questions
Does 99% HPLC purity mean that 99% of the supplied powder is peptide?
No. An area-percentage result describes the integrated chromatographic response under its method. A peptide-content result with a stated mass basis is needed to make a claim about peptide mass in the powder.
Can LC-MS replace a peptide-content assay?
An LC-MS identity result and a quantitative content assay have different purposes. A quantitative LC-MS procedure needs its own calibration and performance justification; a matching mass peak alone is insufficient.
Should every peptide COA report an identical set of tests?
The specification should reflect the material, intended use and risks. Agree the identity, purity, content and other relevant tests before ordering, and state which results are required for the offered batch.
Which documents should accompany a comparison request?
Provide the proposed material identity, quantity basis, intended use and destination, together with the COAs being compared. Include the analytical method references and any reference-standard information available to the buyer.
Sources and further reading
- USP authors, Reference Standards to Support Quality of Synthetic Peptide Therapeutics, Pharmaceutical Research, 2023. Read the paper.
- EMA, ICH Q2(R2): Validation of analytical procedures, current version and scope. Read the guideline page.
For a material enquiry, send the exact identity and quantity basis through our quotation form. Related reading: reading a peptide COA and moisture and vial packaging.